
[Expand/Collapse all sections]Expand all

This document outlines details of PBS-subsidised imatinib, ripretinib
and sunitinib for patients with gastrointestinal stromal tumour (GIST).

GIST and listing dates

Gastrointestinal stromal tumour is a type of tumour occurring in the
gastrointestinal tract, most commonly in the stomach or small intestine.

Listing dates are:

-   imatinib - 1 February 2004 – Metastatic/Unresectable
-   sunitinib - 1 December 2009
-   imatinib - 1 September 2011 – Adjuvant
-   ripretinib - 1 December 2021 – Metastatic/Unresectable

For more information, see Written Authority Required Drugs.

Enquiries

Transfer enquiries about prescription arrangements to the PBS Complex
Drugs Programs team and choose the option relevant to the condition
treated.

The Resources page contains links to application forms, contact details,
item and restriction codes, the PBS schedule and the Services Australia
websites.

Related links

Tier 0 technical support - self-sufficiency

Online Pharmaceutical Benefits Scheme (PBS) Authorities System (OPA
System)

Process telephone Authority approval application

Process written authority approval requests

Processing and National Demand Allocation (PaNDA)

Processing Complex Authority Required Listings

Written Authority Required Drugs

                                   

-   Services Australia ABN 90 794 605 008 
